NeoGenomics (NASDAQ:NEO) : Traders are bullish on NeoGenomics (NASDAQ:NEO) as it has outperformed the S&P 500 by a wide margin of 7.2% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.81%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 13.24% in the last 1 week, and is up 8.93% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 42.30% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $9.23 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $8.46 and the 200 Day Moving Average price is recorded at $7.39.
The stock has recorded a 20-day Moving Average of 12.46% and the 50-Day Moving Average is 9.16%.
NeoGenomics (NASDAQ:NEO): stock turned positive on Friday. Though the stock opened at $8.59, the bulls momentum made the stock top out at $9.23 level for the day. The stock recorded a low of $8.485 and closed the trading day at $9.15, in the green by 12.13%. The total traded volume for the day was 1,597,429. The stock had closed at $8.16 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chairman and CEO) of Neogenomics Inc, Van Oort Douglas M had sold 481,387 shares worth of $4,197,695 in a transaction dated May 26, 2016. In this transaction, 481,387 shares were sold at $8.72 per share.
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing, which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues., and molecular testing, which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at a molecular level.